Stephanie Pinkerton

Stephanie Pinkerton is an accomplished professional in the field of protein therapeutics with extensive experience in research and development. Currently serving as Director of Protein Therapeutics at Enlaza Therapeutics since January 2022, Stephanie previously held the position of Associate Director of Protein Therapeutics at Inception Therapeutics from January 2020 to January 2022. Prior roles include Principal Scientist and Senior Scientist in Protein Chemistry at Pfizer, and Investigator at the California Institute for Biomedical Research, specializing in Antibody Drug Conjugates and Drug Discovery. Stephanie earned a Ph.D. in Chemical Biology from Scripps Research Institute, following a B.S. in Chemistry from Boston College. During their academic career, research focused on antibody conjugates and enantioselective synthesis.